BRPI0810161A2 - Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto - Google Patents

Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto

Info

Publication number
BRPI0810161A2
BRPI0810161A2 BRPI0810161A BRPI0810161A2 BR PI0810161 A2 BRPI0810161 A2 BR PI0810161A2 BR PI0810161 A BRPI0810161 A BR PI0810161A BR PI0810161 A2 BRPI0810161 A2 BR PI0810161A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical
pharmaceutical composition
pharmaceutical preparation
preparation
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
Hakan V Wikstroem
Original Assignee
Nsab Af Neurosearch Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nsab Af Neurosearch Sweden Ab filed Critical Nsab Af Neurosearch Sweden Ab
Publication of BRPI0810161A2 publication Critical patent/BRPI0810161A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0810161 2007-04-12 2008-04-11 Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto BRPI0810161A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0700893 2007-04-12
PCT/SE2008/050414 WO2008127188A1 (en) 2007-04-12 2008-04-11 N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles

Publications (1)

Publication Number Publication Date
BRPI0810161A2 true BRPI0810161A2 (pt) 2014-12-30

Family

ID=39864178

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810161 BRPI0810161A2 (pt) 2007-04-12 2008-04-11 Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto

Country Status (19)

Country Link
US (1) US9139525B2 (enExample)
EP (1) EP2146961B1 (enExample)
JP (1) JP5393654B2 (enExample)
CN (1) CN101711236B (enExample)
AU (1) AU2008239841B2 (enExample)
BR (1) BRPI0810161A2 (enExample)
CA (1) CA2683719C (enExample)
CY (1) CY1115337T1 (enExample)
DK (1) DK2146961T3 (enExample)
ES (1) ES2458592T3 (enExample)
HR (1) HRP20140380T1 (enExample)
IL (1) IL201401A (enExample)
MX (1) MX2009011020A (enExample)
NZ (1) NZ580856A (enExample)
PL (1) PL2146961T3 (enExample)
PT (1) PT2146961E (enExample)
RU (1) RU2470013C2 (enExample)
SI (1) SI2146961T1 (enExample)
WO (1) WO2008127188A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
WO2010058019A1 (en) * 2008-11-24 2010-05-27 Nsab, Filial Af Neurosearch Sweden Ab, Sverige 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9018202B2 (en) * 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
MX343620B (es) 2011-09-07 2016-11-11 Teva Pharmaceuticals Int Gmbh Forma polimorfica de clorhidrato de pridopidina.
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
BR112014024672A8 (pt) 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
EP3419622B1 (en) 2016-02-24 2024-03-06 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
ES2972205T3 (es) 2017-01-20 2024-06-11 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento del síndrome x frágil
HUE061505T2 (hu) 2017-08-14 2023-07-28 Prilenia Neurotherapeutics Ltd Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel
JP2020532517A (ja) 2017-08-30 2020-11-12 プリレニア ニューロセラピューティクス リミテッド 高濃度プリドピジン製剤
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
AU2020243692B2 (en) 2019-03-15 2023-03-02 Prilenia Neurotherapeutics Ltd. Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1217296A (en) 1917-01-11 1917-02-27 Lewis A Peckham Shock-absorber.
US2813098A (en) 1955-08-16 1957-11-12 Upjohn Co 3-methoxy-n-methylmorphinan n-oxide
US2813097A (en) 1955-08-16 1957-11-12 Upjohn Co 3-hydroxy-n-methylmorphinan-n-oxide
US3131185A (en) 1959-03-18 1964-04-28 Orsymonde Nicotinic esters of hydroxyl derivatives of the phenanthrenic alkaloids of opium, and process for the preparation of these esters
BE638369A (enExample) 1962-10-10
CH481124A (de) 1966-09-21 1969-11-15 Geigy Ag J R Verfahren zur Herstellung von neuen, kondensierten heterocyclischen Verbindungen
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
DK0641320T3 (da) * 1991-04-17 2001-08-20 Upjohn Co Substituerede (S)-3-phenylpiperidinderivater, deres fremstilling og deres anvendelse som dopaminautoreceptorantagonister
AU676993B2 (en) 1991-06-27 1997-04-10 Virginia Commonwealth University Sigma receptor ligands and the use thereof
IL112099A (en) * 1993-12-23 1999-07-14 Ortho Pharma Corp N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
US6121259A (en) * 1998-11-23 2000-09-19 Sepracor Inc. Olanzapine-N-oxide compositions and methods
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE0200301D0 (sv) * 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
MXPA06013941A (es) * 2004-06-08 2007-12-10 Neurosearch Sweden Ab Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina.
CA2569843A1 (en) 2004-06-08 2005-12-22 A. Carlsson Research Ab New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
WO2006020573A2 (en) * 2004-08-11 2006-02-23 Barbeau Donald L Noncardiotoxic pharmaceutical compounds
ES2659577T3 (es) * 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
JP2009504799A (ja) * 2005-08-22 2009-02-05 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ピペラジンおよびピペリジン誘導体のプロドラッグとしてのｎ−オキシド
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
UA96756C2 (en) * 2006-05-02 2011-12-12 Эббот Хелскеа Продактс Б.В. N-oxides of pyridylmethylpiperazine and -piperidine derivatives
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US20130203886A1 (en) * 2010-03-05 2013-08-08 Nileshkumar Prakash Kukalyekar Process for the production of an uhmwpe article
NZ608120A (en) * 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
MX343620B (es) 2011-09-07 2016-11-11 Teva Pharmaceuticals Int Gmbh Forma polimorfica de clorhidrato de pridopidina.
EP2787997A4 (en) * 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
BR112014024672A8 (pt) * 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
MX2015003812A (es) * 2012-09-27 2015-07-17 Teva Pharma Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.
US20150209346A1 (en) * 2012-09-27 2015-07-30 Teva Pharmaceutical Industries, Ltd. Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease

Also Published As

Publication number Publication date
CA2683719C (en) 2015-07-14
ES2458592T3 (es) 2014-05-06
PT2146961E (pt) 2014-04-30
IL201401A0 (en) 2010-05-31
EP2146961A1 (en) 2010-01-27
JP5393654B2 (ja) 2014-01-22
NZ580856A (en) 2011-11-25
RU2470013C2 (ru) 2012-12-20
SI2146961T1 (sl) 2014-08-29
US9139525B2 (en) 2015-09-22
EP2146961B1 (en) 2014-01-29
AU2008239841A1 (en) 2008-10-23
CN101711236A (zh) 2010-05-19
PL2146961T3 (pl) 2014-09-30
MX2009011020A (es) 2009-10-30
US20100105736A1 (en) 2010-04-29
RU2009141300A (ru) 2011-05-20
DK2146961T3 (da) 2014-04-28
WO2008127188A1 (en) 2008-10-23
IL201401A (en) 2015-10-29
JP2010523651A (ja) 2010-07-15
EP2146961A4 (en) 2011-08-03
HRP20140380T1 (hr) 2014-08-15
AU2008239841B2 (en) 2013-07-18
CN101711236B (zh) 2012-10-31
CY1115337T1 (el) 2017-01-04
CA2683719A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0812942A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
BRPI0819696A2 (pt) Compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0609802A2 (pt) composto, composição farmacêutica e uso de um composto
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
BRPI0716698A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0818193A2 (pt) composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112013015397A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0915473A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0918517A2 (pt) composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: IVAX INTERNATIONAL GMBH (CH)

B25G Requested change of headquarter approved

Owner name: IVAX INTERNATIONAL GMBH (CH)

B25D Requested change of name of applicant approved

Owner name: TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2509 DE 05-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.